We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Horizon Rescinds Bid to Acquire Depomed

Horizon Rescinds Bid to Acquire Depomed

November 30, 2015

Horizon Pharma has withdrawn its roughly $1 billion unsolicited bid to acquire specialty pharmaceutical company Depomed after a California judge ruled that Horizon improperly used confidential information.

Horizon had been seeking injunctive relief regarding the legality of Depomed's poison pill from Judge Peter Kirwan of the Superior Court of California. Depomed, meanwhile, had filed a motion for preliminary injunction, accusing Horizon of improperly using information about the pain therapy Nucynta (tapentadol) that it obtained through a confidentiality agreement entered into as part of a competitive bidding process for the drug. Both Horizon and Depomed were involved in the bidding process, wooing Janssen Pharmaceuticals, a unit of Johnson & Johnson.

Ultimately, Depomed emerged as the winner for Nucynta; however, it accused Horizon of turning around and using nonpublic information about the drug to try and take over its rival. For its part, Horizon maintained the confidentiality agreement applied only to a co-promotion agreement involving Nucynta and Horizon’s Duexis (ibuprofen/famotidine) that was abandoned by the J&J unit in March 2014. The confidentiality agreement did not extend to the Nucynta auction, Horizon said, a position with which Depomed — and the court — disagreed.

Despite the setback, Horizon says the ruling does not affect its 2016 guidance or long-range plans.

The ruling came a week after Express Scripts filed suit against Horizon seeking to recover roughly $140 million, contending it refused to honor contractual obligations under a manufacturer rebate agreement.

Court documents detailing Kirwan’s decision are available here: www.fdanews.com/11-23-15-depomed.pdf.

Pharmaceuticals Commercial Operations

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

  • FDA Expands Approval of Pfizer and Myovant’s Myfembree to Include Endometriosis

  • FDA Provides Update on Haimen Shengbang Laboratory’s Recall of Its Viral Transport Media Containers

  • FDA Issues EUA for Monkeypox Vaccine

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing